|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
From the Department of Haematology, Hammersmith
Hospital/ICSM, London, United Kingdom.
An analysis was performed of the response to treatment with donor
lymphocyte infusions (DLI) and the survival in 66 consecutive patients
who relapsed after primary treatment by allogeneic stem cell
transplantation for BCR-ABL-positive chronic myeloid leukemia. The
transplant donor was an HLA-identical sibling (n = 35) or a
"matched" unrelated volunteer (n = 31). Fifty-seven patients were
transplanted in chronic phase, eight in accelerated phase, and one in
second chronic phase. The recognition of relapse was based on precise
molecular, cytogenetic, or hematologic criteria. The median interval
from transplant to relapse was 12 months (range 3-85). The median
interval from relapse to initiation of DLI was 9.4 months (range 1-70).
Patients received DLI from their original transplant donors on a
bulk-dose (n = 34) or on an escalating-dose (n = 32) regimen.
Patients were monitored serially by hematologic, cytogenetic, and
molecular criteria. Molecular remission was defined by the finding of
negative results by nested primer reverse transcriptase polymerase
chain reaction (RT-PCR) for BCR-ABL transcripts on two consecutive
occasions, subject to satisfactory controls. Forty-four patients (67%)
achieved molecular remission. Patients who had relapsed to advanced
phase disease and patients with short intervals between transplant and
relapse had significantly lower probabilities of achieving molecular
remission. Of the 44 patients who achieved molecular remission, 4 reverted to a PCR-positive status at 15, 18, 37, and 87 weeks after
remission. The probability of survival for patients who achieved
molecular remission was significantly better than for those who failed
to do so (95% versus 53% at 3 years post-DLI,
P = .0001). We conclude that the majority of molecular remissions after DLI are durable, and thus the majority of responding patients may prove to have been cured.
(Blood. 2000;96:2712-2716) Allogeneic hematopoietic stem cell
transplantation (SCT) is currently the only procedure capable of curing
patients with chronic myeloid leukemia (CML)1,2. One of the
major causes of treatment failure after allogeneic SCT is
relapse. The actuarial probability of relapse is very low for patients
allografted in chronic phase with unmanipulated marrow cells and the
use of cyclosporine alone as graft-versus-host disease (GVHD)
prophylaxis. If, however, the prophylaxis for GVHD is more
intensive, as for example when donor marrow cells are T-cell
depleted3 or when methotrexate is added to
cyclosporine,4 the incidence of relapse is much higher. The
incidence of relapse is also higher when the transplant is performed in
patients with the advanced phase of CML.5
A number of approaches can be considered to treat patients with CML in
relapse after allografting. Although a second allograft produces
sustained molecular remission in a proportion of patients, it is
associated with a substantial mortality.6 Administration of
interferon- We have shown that quantitative reverse transcriptase polymerase
chain reaction (RT-PCR) for BCR-ABL transcripts is useful for
monitoring patients after allogeneic SCT. A persistently negative RT-PCR finding after transplant predicts a durable remission, whereas
rising levels of BCR-ABL transcripts usually precede cytogenetic relapse.15 Although the clinical value of RT-PCR data
after SCT for CML has been questioned by some,16 we have
in practice used these data to define relapse and to indicate the need
for further treatment on a routine basis. Thus, we decided to apply the
same approach to monitor the DLI treatment. We report here results of
treating by DLI 66 consecutive patients who relapsed after allogeneic
SCT. We assessed the response primarily on the basis of molecular
studies for BCR-ABL transcripts and correlated results with incidence
and durability of molecular remission.
Patients and transplant procedure
Post-transplant monitoring
At each clinic visit, full blood counts were performed. For patients transplanted before 1991, samples of bone marrow were aspirated regularly for cytogenetic examination. Cytogenetic studies of bone marrow metaphases were carried out on Giemsa-stained metaphases, using standard techniques. A minimum of 30 marrow metaphases were analyzed whenever possible. Since 1991, peripheral blood samples were studied at intervals of 1 to 3 months after transplant for the presence of BCR-ABL transcripts by a multiplex and/or a two-step RT-PCR. Results were expressed as the ratio between BCR-ABL and ABL transcript numbers (BCR-ABL/ABL ratio).19,20 Patients were judged to be in continuing complete remission post-transplant if RT-PCR studies were negative or were positive at low level and failed to satisfy the criteria for molecular relapse defined below. If BCR-ABL/ABL ratio were raised, cytogenetic studies using standard techniques were performed on bone marrow metaphases. The frequency of cytogenetic and RT-PCR monitoring after SCT was similar for recipients of sibling donor and VUD transplants. Definitions of relapse In general, relapse of CML after allogeneic SCT can be recognized first as a result of a progressive rise in the numbers of BCR-ABL transcripts in the blood; subsequently Ph-positive metaphases can be identified in the marrow and eventually patients show features of hematologic relapse. Occasionally molecular or cytogenetic relapses are reversible but such transient relapses are rare.15 The 66 patients in this series satisfied criteria for molecular, cytogenetic, or hematologic relapse at the time when treatment with DLI was initiated (Table 1). A patient was considered to be in molecular relapse if his or her BCR-ABL/ABL ratio remained at or exceeded a level thought to reflect a burden of CML approximately 50-fold less than that seen in early cytogenetic relapse.15,20 In practice, we used the following criteria: a patient was considered to be in molecular relapse if over a minimum of 4 weeks the BCR-ABL/ABL ratio exceeded 0.02% in 3 samples, or exceeded 0.05% in 2 samples, or showed rising levels with the last 2 samples higher than 0.02%. These criteria were adopted to avoid classifying as relapse the occasional patient who had fluctuating low levels of BCR-ABL transcripts. Cytogenetic relapse was defined if one or more Ph-positive metaphase was detected without evidence of hematologic relapse. Hematologic relapse was diagnosed in the presence of peripheral blood leukocytosis, usually with predominance of myelocytes and neutrophils in the differential count, accompanied by a hypercellular bone marrow with Ph chromosome positivity on cytogenetic analysis. In a number of patients transplanted before 1991, serial molecular data were not available, and, therefore, relapse was recognized first by cytogenetic or hematologic criteria. The phase of CML was classified in accordance with criteria proposed by the International Bone Marrow Transplant Registry.21 We used the term advanced phase to include both accelerated and blastic phases. These criteria were used to define the stage of disease both at the time of transplantation and at hematologic relapse.
Management of relapse with DLI Sixty-six patients relapsed after allogeneic SCT at a median time of 12 months (range 3-85). The diagnosis of relapse was based on the molecular (n = 33), cytogenetic (n = 28), or hematologic (n = 5) criteria defined above. At diagnosis of relapse, the only patient who was still receiving immunosuppression had the drugs discontinued. In general, preparations were made for administration of DLI as soon as this could conveniently be scheduled. The median time between relapse and DLI was 10 months (range 1-70). In some cases the stage of relapse had progressed during this interval. Thus, at the time of DLI, 8 patients were in molecular relapse, 19 were in cytogenetic relapse, and in 39 the disease was detectable at the hematologic level (30 in chronic phase and 9 in advanced phase). Thirty-four of the patients received a single infusion of donor lymphocytes from their original transplant donor (bulk-dose regimen). The median dose of lymphocytes transfused was 1.5 × 108/kg (range 0.4-5.3). Thirty-two patients received lymphocytes from their original donor, administered according to an escalating-dose schedule as previously described (escalating-dose regimen).22 Briefly, for sibling transplant recipients the target doses of CD3+ cells/kg were sequentially 107, 5 × 107, and 108, whereas for VUD recipients the target doses were 106, 107, 5 × 107, and 108. Each patient was assessed with RT-PCR and/or cytogenetic studies 12 weeks after the preceding dose, and a further dose of lymphocytes was planned if there was no clear evidence of response; in practice the median interval between doses was 20 weeks (range 12-33 weeks). All patients included in this report completed the full protocol, that is, they were treated until they responded or until they were deemed refractory to DLI. The management of patients pre- and post-BDR DLI has been described elsewhere.22,23Definition of molecular remission post-DLI RT-PCR was performed at 4-week intervals or more frequently after initiation of DLI. Molecular remission was defined as the absence of detectable BCR-ABL transcripts by RT-PCR analysis of peripheral blood on 2 consecutive occasions. To control for sample quality in BCR-ABL-negative specimens, complementary DNA (cDNA) was considered evaluable only if it contained at least 2 × 104 normal ABL transcripts/5 µL cDNA. This ensured that the absence of BCR-ABL transcripts could be excluded at a sensitivity of at least 5 × 10 5.24
Statistical methods The probabilities of survival, achieving molecular remission, and relapse post-DLI were calculated, using the methods of Kaplan and Meier25 and cumulative incidence.26 An initial analysis comparing prognostic groups for molecular remission was carried out using the log-rank test. Those variables significant at the P < .2 level in univariate analyses were further examined by using proportional hazards regression analysis employing a backward-stepping procedure to identify the most statistically significant model. All P values are 2-sided. Confidence intervals refer to 95% boundaries.
Molecular response and durability of remission after DLI Forty-four patients had a negative result RT-PCR on at least 2 occasions after administration of DLI and thus satisfied our criteria for molecular remission; the probability of achieving molecular remission at 3 years post-DLI was 68% (Figure 1). The median follow-up after molecular remission was 29 months (range 5-89). Ten patients had one BCR/ABL negative result, followed by BCR/ABL positivity, and later satisfied our criteria for molecular remission. The intervals between this initial negative result and subsequent molecular remission were 21, 34, 46, 62, 70, 92, 143, 154, 441, and 1069 days, respectively.
In 30 patients (68%), the duration of molecular
remission post-DLI exceeded the duration of molecular remission
post-SCT (Figure 2).
Survival post-DLI Patients who achieved molecular remission post-DLI had significantly improved survival when compared with those who failed to achieve molecular remission (95% versus 53% at 3 years post-DLI, P = .0001; Figure 3). Of the 3 patients in molecular remission who died, one had relapsed in blastic phase, one died of infectious complications during chronic GVHD, and one died of unknown causes. Three patients treated with DLI in accelerated phase died early after treatment (days 24, 46, and 49).
Prognostic factors for molecular remission post-DLI Previous studies have shown that disease stage at time of DLI, donor match, and choice of GVHD prophylaxis are important in determining the efficacy of DLI in inducing molecular remission. Univariate analyses performed in this study confirmed the importance of the above factors (Table 1). However, on further examination with multivariate methods, the only adverse effects were advanced phase disease at the time of starting DLI and a relatively short interval between SCT and relapse (Table 2). Our data suggest that disease recurrence early after SCT (< 9 months) was less likely to respond to DLI. In patients relapsing less than 9 months post-SCT, failure to respond to DLI correlated with disease stage at relapse (Table 3).
Probability of PCR positivity after molecular remission Of the 44 patients achieving molecular remission, 4 subsequently became PCR positive (Figure 4A-C). Their PCR negativity lasted 15, 18, 37, and 87 weeks. Their median follow-up was 29 months (range 5-89). Noteworthy, all these patients had received DLI according to the escalating-dose regimen. One patient progressed to a blastic phase and died (Figure 4A). The other 3 patients showed fluctuating levels of BCR-ABL transcripts; of these, 2 patients fulfilled the criteria for molecular relapse and received a further dose of donor cells that further restored remission (Figure 4B-C).
Although DLI is highly effective in restoring remission in patients who relapse after allogeneic SCT for CML, the durability of these remissions is not yet known. The very few data generated so far are inconclusive because the definition of remission has not been consistent, and, therefore, the final outcome for patients achieving different levels of remission can be significantly different. We have demonstrated that, after transplant, only patients who do not show or show very low levels of BCR-ABL transcripts for a prolonged period of time experience long-term remissions.12,13,27 On the basis of such evidence, we decided to adopt molecular remission as a reference to assess the long-term outcome of 66 consecutive patients receiving DLI for CML in relapse after allografting. The probability of attaining molecular remission was 68% at 3 years post-DLI (Figure 1). Notably, of all the patients responding to DLI in our study, only 2 achieved a cytogenetic remission but failed to achieve molecular remission. One of these patients progressed to a cytogenetic relapse 46 months after the first evidence of cytogenetic remission; he remains alive, but further DLI could not be given because his sibling donor is no longer available. The other patient has recently received a lymphocyte dose (2 × 108 CD3+ cells/kg) higher than the maximum dose scheduled in our escalating protocol and his BCR-ABL transcripts have been falling. In this analysis, we have shown that patients who relapse within 9 months after allografting are less likely to respond to DLI than patients who relapse relatively late after allografting (Table 1). We have shown previously that patients whose relapse was based on molecular or cytogenetic criteria have a higher rate of response to DLI than those whose relapse was based on hematologic criteria.11 This observation was confirmed in this study, but the superior response rate of patients diagnosed at the molecular and cytogenetic levels was more obvious in patients diagnosed early after allografting than in those diagnosed more than 9 months after the procedure (Table 3). These findings support the notion that the tumor burden at the time of relapse correlates with the probability of response to DLI. However, they may also reflect differing tempos of disease in different patients, whereby patients whose disease progresses relatively rapidly to hematologic relapse may be more resistant to remission induction by DLI than those whose disease relapses only relatively slowly. A large multicenter study of the results of DLI reported recently from the United States showed that the optimal response to DLI was obtained when the interval from SCT to DLI was less than 2 years.13 However, we were unable to show any difference in response rate when we compared response rates between patients treated within and beyond 2 years from the original transplantation (P = .86). It should be noted that the interval from transplant to DLI comprises the interval from transplant to diagnosis of relapse plus the interval from relapse to initiation of DLI. Thus, these discordant results might be explained if the interval from SCT to diagnosis of relapse was a more important determinant of response than the interval from transplant to initiation of treatment. The patients included in the 2 studies were not in fact comparable with regard to the interval from transplantation to diagnosis of relapse. The 44 patients who achieved molecular remission showed a better survival than those who failed to achieve molecular remission (Figure 3). Of the 3 patients who died after achieving molecular remission, only one had evidence of leukemia at the time of death. It is worth noting that, for 68% of patients who achieved molecular remission, its duration already exceeds the duration of remission after the original transplant procedure (Figure 2). Thus, in these patients the DLI was more effective than the lymphocytes administered at the time of transplant. This benefit may reflect the higher lymphocyte dose at DLI, the lack of post-DLI immunosuppression, and the status of graft-versus-host tolerance induced at the time of the original transplantation. Four patients who achieved molecular remission subsequently became positive for BCR-ABL transcripts. The one patient who proceeded to frank hematologic relapse had been PCR-negative for only 15 weeks (Figure 4A). Two other patients had levels of BCR-ABL transcripts equivalent to those that we have used to diagnose molecular relapse and to initiate DLI after an allograft. Both received a further dose of DLI: one has regained molecular remission that has lasted thus far 15 weeks (Figure 4B); the molecular status of the other patient is unchanged 8 weeks post-DLI. The fourth patient had persistently fluctuating levels of BCR-ABL transcripts with intermittent negative readings for 10 months (Figure 4C). He received no further treatment, but thereafter his PCR status has been persistently negative for 12 weeks. It is tempting to speculate that donor T cells may have a limited period of activity, but that they can be reactivated in certain circumstances. It should be noted that these four patients all received DLI according to the escalating-dose regimen, which suggests that in these cases the cell dose administered may have reduced the number of residual leukemia cells to a level undetectable by PCR but still sufficient to regenerate the disease. Our study shows that molecular remissions post-DLI are durable and thus that survival is best for patients in whom molecular evidence of leukemia cannot be detected. Although we cannot exclude the possibility that patients who satisfy less stringent criteria for remission may survive equally well, we suggest that molecular remission should be the aim of DLI treatment.
Submitted February 7, 2000; accepted June 14, 2000.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Francesco Dazzi, Department of Haematology, Hammersmith Hospital/ ICSM, Du Cane Rd, London W12 0NN, United Kingdom; e-mail: f.dazzi{at}ic.ac.uk.
1. Goldman JM, Apperley JF, Jones L, et al. Bone marrow transplantation for patients with chronic myeloid leukemia. N Engl J Med. 1986;314:202-207[Abstract]. 2. Thomas ED, Clift RA, Fefer A, et al. Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med. 1986;104:155-163. 3. Goldman JM, Gale RP, Horowitz MM, et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Ann Intern Med. 1988;108:806-814.
4.
Storb R, Deeg HJ, Pepe M, et al.
Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial.
Blood.
1989;73:1729-1734 5. Gratwohl A, Hermans J, Goldman JM, et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet. 1998;352:1087-1092[Medline] [Order article via Infotrieve].
6.
Arcese W, Goldman JM, D'Arcangelo E, et al.
Outcome for patients who relapse after allogeneic bone marrow transplantation for chronic myeloid leukemia. Chronic Leukemia Working Party. European Bone Marrow Transplantation Group.
Blood.
1993;82:3211-3219
7.
Higano CS, Chielens D, Raskind W, et al.
Use of alpha-2a-interferon to treat cytogenetic relapse of chronic myeloid leukemia after marrow transplantation.
Blood.
1997;90:2549-2554
8.
Kolb HJ, Mittermuller J, Clemm C, et al.
Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients.
Blood.
1990;76:2462-2465
9.
Cullis JO, Jiang YZ, Schwarer AP, Hughes TP, Barrett AJ, Goldman JM.
Donor leukocyte infusions for chronic myeloid leukemia in relapse after allogeneic bone marrow transplantation.
Blood.
1992;79:1379-1381 10. Dazzi F, Szydlo RM, Goldman JM. Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplant: where we now stand. Exp Hematol. 1999;27:1477-1486[Medline] [Order article via Infotrieve].
11.
van Rhee F, Lin F, Cullis JO, et al.
Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse.
Blood.
1994;83:3377-3383
12.
Kolb HJ, Schattenberg A, Goldman JM, et al.
Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia.
Blood.
1995;86:2041-2050
13.
Collins RH Jr, Shpilberg O, Drobyski WR, et al.
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
J Clin Oncol.
1997;15:433-444 14. Raanani P, Dazzi F, Sohal J, et al. The rate and kinetics of molecular response to donor leucocyte transfusions in chronic myeloid leukaemia patients treated for relapse after allogeneic bone marrow transplantation. Br J Haematol. 1997;99:945-950[Medline] [Order article via Infotrieve].
15.
Lin F, van Rhee F, Goldman JM, Cross NC.
Kinetics of increasing BCR-ABL transcript numbers in chronic myeloid leukemia patients who relapse after bone marrow transplantation.
Blood.
1996;87:4473-4478
16.
Faderl S, Talpaz M, Kantarjian HM, Estrov Z.
Should polymerase chain reaction analysis to detect minimal residual disease in patients with chronic myelogenous leukemia be used in clinical decision making?
Blood.
1999;93:2755-2759
17.
Spencer A, Szydlo RM, Brookes PA, et al.
Bone marrow transplantation for chronic myeloid leukemia with volunteer unrelated donors using ex vivo or in vivo T-cell depletion: major prognostic impact of HLA class I identity between donor and recipient.
Blood.
1995;86:3590-3597 18. Savage DG, Szydlo RM, Chase A, Apperley JF, Goldman JM. Bone marrow transplantation for chronic myeloid leukaemia: the effects of differing criteria for defining chronic phase on probabilities of survival and relapse. Br J Haematol. 1997;99:30-35[Medline] [Order article via Infotrieve].
19.
Hochhaus A, Lin F, Reiter A, et al.
Quantification of residual disease in chronic myelogenous leukemia patients on interferon-alpha therapy by competitive polymerase chain reaction.
Blood.
1996;87:1549-1555 20. Cross NC. Minimal residual disease in chronic myeloid leukaemia. Hematol Cell Ther. 1998;40:224-228[Medline] [Order article via Infotrieve]. 21. Clift R, Goldman J, Gratwohl A, Horowitz M. Proposals for standardized reporting of results of bone marrow transplantation for leukaemia. Bone Marrow Transplant. 1989;4:445-448[Medline] [Order article via Infotrieve].
22.
Dazzi F, Szydlo RM, Craddock C, et al.
Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia.
Blood.
2000;95:67-71 23. van Rhee F, Savage D, Blackwell J, et al. Adoptive immunotherapy for relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: equal efficacy of lymphocytes from sibling and matched unrelated donors. Bone Marrow Transplant. 1998;21:1055-1061[Medline] [Order article via Infotrieve].
24.
Cross NC, Feng L, Chase A, Bungey J, Hughes TP, Goldman JM.
Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation.
Blood.
1993;82:1929-1936 25. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:547-581. 26. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18:695-706[Medline] [Order article via Infotrieve]. 27. Porter DL, Collins RH Jr, Shpilberg O, et al. Long-term follow-up of patients who achieved complete remission after donor leukocyte infusions. Biol Blood Marrow Transplant. 1999;5:253-261[Medline] [Order article via Infotrieve].
© 2000 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  A. S. M. Yong, K. Keyvanfar, N. Hensel, R. Eniafe, B. N. Savani, M. Berg, A. Lundqvist, S. Adams, E. M. Sloand, J. M. Goldman, et al. Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib Blood, January 22, 2009; 113(4): 875 - 882. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. S. Majhail Old and New Cancers after Hematopoietic-Cell Transplantation Hematology, January 1, 2008; 2008(1): 142 - 149. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Mackinnon Donor Lymphocyte Infusion after Allogeneic Stem Cell Transplantation ASCO Educational Book, January 1, 2008; 2008(1): 334 - 337. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Kebriaei, M. A. Detry, S. Giralt, A. Carrasco-Yalan, A. Anagnostopoulos, D. Couriel, I. F. Khouri, P. Anderlini, C. Hosing, A. Alousi, et al. Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia Blood, November 1, 2007; 110(9): 3456 - 3462. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Miller, D. J. Weisdorf, L. J. Burns, A. Slungaard, J. E. Wagner, M. R. Verneris, S. Cooley, R. Wangen, S. K. Fautsch, R. Nicklow, et al. Lymphodepletion followed by donor lymphocyte infusion (DLI) causes significantly more acute graft-versus-host disease than DLI alone Blood, October 1, 2007; 110(7): 2761 - 2763. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. S. M. Yong, K. Rezvani, B. N. Savani, R. Eniafe, S. Mielke, J. M. Goldman, and A. J. Barrett High PR3 or ELA2 expression by CD34+ cells in advanced-phase chronic myeloid leukemia is associated with improved outcome following allogeneic stem cell transplantation and may improve PR1 peptide-driven graft-versus-leukemia effects Blood, July 15, 2007; 110(2): 770 - 775. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. O. Butler, J.-S. Lee, S. Ansen, D. Neuberg, F. S. Hodi, A. P. Murray, L. Drury, A. Berezovskaya, R. C. Mulligan, L. M. Nadler, et al. Long-Lived Antitumor CD8+ Lymphocytes for Adoptive Therapy Generated Using an Artificial Antigen-Presenting Cell Clin. Cancer Res., March 15, 2007; 13(6): 1857 - 1867. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X.-J. Huang, D.-H. Liu, K.-Y. Liu, L.-P. Xu, H. Chen, and W. Han Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched/haploidentical T-cell-replete hematopoietic stem cell transplantation Haematologica, March 1, 2007; 92(3): 414 - 417. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Hughes, M. Deininger, A. Hochhaus, S. Branford, J. Radich, J. Kaeda, M. Baccarani, J. Cortes, N. C. P. Cross, B. J. Druker, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results Blood, July 1, 2006; 108(1): 28 - 37. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Kaeda, D. O'Shea, R. M. Szydlo, E. Olavarria, F. Dazzi, D. Marin, S. Saunders, J. S. Khorashad, N. C. P. Cross, J. M. Goldman, et al. Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy Blood, May 15, 2006; 107(10): 4171 - 4176. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Crawley, R. Szydlo, M. Lalancette, A. Bacigalupo, A. Lange, M. Brune, G. Juliusson, A. Nagler, A. Gratwohl, J. Passweg, et al. Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT Blood, November 1, 2005; 106(9): 2969 - 2976. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Tefferi, G. W. Dewald, M. L. Litzow, J. Cortes, M. J. Mauro, M. Talpaz, and H. M. Kantarjian Chronic Myeloid Leukemia: Current Application of Cytogenetics and Molecular Testing for Diagnosis and Treatment Mayo Clin. Proc., March 1, 2005; 80(3): 390 - 402. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Kami, A. Makimoto, Y. Heike, and Y. Takaue Reduced-intensity Hematopoietic Stem Cell Transplantation (RIST) for Solid Malignancies Jpn. J. Clin. Oncol., December 1, 2004; 34(12): 707 - 716. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-J. Kolb, C. Schmid, A. J. Barrett, and D. J. Schendel Graft-versus-leukemia reactions in allogeneic chimeras Blood, February 1, 2004; 103(3): 767 - 776. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. A. Bethge, U. Hegenbart, M. J. Stuart, B. E. Storer, M. B. Maris, M. E. D. Flowers, D. G. Maloney, T. Chauncey, B. Bruno, E. Agura, et al. Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning Blood, February 1, 2004; 103(3): 790 - 795. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. W. Soper, M. D. Lessard, C. D. Jude, A. J. T. Schuldt, R. M. Bunte, and J. E. Barker Successful Allogeneic Neonatal Bone Marrow Transplantation Devoid of Myeloablation Requires Costimulatory Blockade J. Immunol., September 15, 2003; 171(6): 3270 - 3277. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Cwynarski, I. A. G. Roberts, S. Iacobelli, A. van Biezen, R. Brand, A. Devergie, J. M. Vossen, M. Aljurf, W. Arcese, F. Locatelli, et al. Stem cell transplantation for chronic myeloid leukemia in children Blood, August 15, 2003; 102(4): 1224 - 1231. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Renga, P. Pedrazzoli, and S. Siena Present results and perspectives of allogeneic non-myeloablative hematopoietic stem cell transplantation for treatment of human solid tumors Ann. Onc., August 1, 2003; 14(8): 1177 - 1184. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Marktel, Z. Magnani, F. Ciceri, S. Cazzaniga, S. R. Riddell, C. Traversari, C. Bordignon, and C. Bonini Immunologic potential of donor lymphocytes expressing a suicide gene for early immune reconstitution after hematopoietic T-cell-depleted stem cell transplantation Blood, February 15, 2003; 101(4): 1290 - 1298. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-C. Meunier, G. Roy-Proulx, N. Labrecque, and C. Perreault Tissue distribution of target antigen has a decisive influence on the outcome of adoptive cancer immunotherapy Blood, January 15, 2003; 101(2): 766 - 770. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Robertson, D. Pelloso, R. Abonour, R. A. Hromas, R. P. Nelson Jr., L. Wood, and K. Cornetta Interleukin 12 Immunotherapy after Autologous Stem Cell Transplantation for Hematological Malignancies Clin. Cancer Res., November 1, 2002; 8(11): 3383 - 3393. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. I. Marks, R. Lush, J. Cavenagh, D. W. Milligan, S. Schey, A. Parker, F. J. Clark, L. Hunt, J. Yin, S. Fuller, et al. The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation Blood, October 16, 2002; 100(9): 3108 - 3114. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Dazzi, R. M. Szydlo, J. F. Apperley, and J. M. Goldman Prognostic factors for acute graft-versus-host disease after donor lymphocyte infusions Blood, September 18, 2002; 100(7): 2673 - 2673. [Full Text] [PDF]
|
|
|
|
|
|
C. Guglielmi, W. Arcese, F. Dazzi, R. Brand, D. Bunjes, L. F. Verdonck, A. Schattenberg, H.-J. Kolb, P. Ljungman, A. Devergie, et al. Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose Blood, June 28, 2002; 100(2): 397 - 405. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Olavarria, C. Craddock, F. Dazzi, D. Marin, S. Marktel, J. F. Apperley, and J. M. Goldman Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantation Blood, May 15, 2002; 99(10): 3861 - 3862. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. E. Levine, T. Braun, S. L. Penza, P. Beatty, K. Cornetta, R. Martino, W. R. Drobyski, A. J. Barrett, D. L. Porter, S. Giralt, et al. Prospective Trial of Chemotherapy and Donor Leukocyte Infusions for Relapse of Advanced Myeloid Malignancies After Allogeneic Stem-Cell Transplantation J. Clin. Oncol., January 15, 2002; 20(2): 405 - 412. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. J. Druker, S. G. O'Brien, J. Cortes, and J. Radich Chronic Myelogenous Leukemia Hematology, January 1, 2002; 2002(1): 111 - 135. [Abstract] [Full Text]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2000 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
may produce good hematologic control, but the molecular
response is rarely sustained.
